Anebulo Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2021 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Anebulo Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2021 to 2024.
  • Anebulo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$1.35M, a 45.9% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$8.2M, a 30.1% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$8.2M, a 30.1% increase from 2023.
  • Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$11.7M, a 71.9% decline from 2022.
  • Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$6.83M, a 77.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$8.2M +$3.53M +30.1% Jul 1, 2023 Jun 30, 2024 10-K 2024-09-25
2023 -$11.7M -$4.91M -71.9% Jul 1, 2022 Jun 30, 2023 10-K 2024-09-25
2022 -$6.83M +$23.4M +77.4% Jul 1, 2021 Jun 30, 2022 10-K 2023-09-22
2021 -$30.3M Jul 1, 2020 Jun 30, 2021 10-K 2022-09-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.